AIM: To compare clinical, cost-effect efficacies and safety of simvastatin Zokor and generic Vasilip in correction of dislipoproteinemia in patients with ischemic heart disease. MATERIAL AND METHODS: The original statin Zokor and generic statin Vasilip were given for 8 weeks in a dose 20 mg/day. RESULTS: Vasilip and Zokor demonstrated similar hypolipidemic efficacy and safety, but Vasilip administration was more cost-effective. CONCLUSION: Simvastatin Vasilip is recommended for wider use in clinical practice because it is clinically and cost effective.
AIM: To compare clinical, cost-effect efficacies and safety of simvastatin Zokor and generic Vasilip in correction of dislipoproteinemia in patients with ischemic heart disease. MATERIAL AND METHODS: The original statin Zokor and generic statin Vasilip were given for 8 weeks in a dose 20 mg/day. RESULTS: Vasilip and Zokor demonstrated similar hypolipidemic efficacy and safety, but Vasilip administration was more cost-effective. CONCLUSION:Simvastatin Vasilip is recommended for wider use in clinical practice because it is clinically and cost effective.